With refer to earlier letter dated October 17, 2020 informing about entering into a share purchase agreement to acquire 100% equity share capital of MViyeS Pharma Ventures (MViyeS), Aurobindo Pharma has informed that the aforesaid acquisition has been completed on November 6, 2020. Before acquisition, MViyeS was holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the Company is holding the balance 67.82%. Now, both Eugia Pharma Specialities and MViyeS Pharma Ventures have become 100% subsidiaries of the Company.
The above information is a part of company’s filings submitted to BSE.
